477 related articles for article (PubMed ID: 27902670)
1. Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises.
Hagedorn JM; Monico EC
Pediatr Emerg Care; 2019 Jan; 35(1):78-79. PubMed ID: 27902670
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
[TBL] [Abstract][Full Text] [Related]
3. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease.
Tawfic QA; Faris AS; Kausalya R
J Pain Symptom Manage; 2014 Feb; 47(2):334-40. PubMed ID: 23856095
[TBL] [Abstract][Full Text] [Related]
4. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial.
Lubega FA; DeSilva MS; Munube D; Nkwine R; Tumukunde J; Agaba PK; Nabukenya MT; Bulamba F; Luggya TS
Scand J Pain; 2018 Jan; 18(1):19-27. PubMed ID: 29794277
[TBL] [Abstract][Full Text] [Related]
5. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Neri CM; Pestieau SR; Darbari DS
Paediatr Anaesth; 2013 Aug; 23(8):684-9. PubMed ID: 23565738
[TBL] [Abstract][Full Text] [Related]
6. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature.
Uprety D; Baber A; Foy M
Ann Hematol; 2014 May; 93(5):769-71. PubMed ID: 24232306
[TBL] [Abstract][Full Text] [Related]
7. Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial.
Young JR; Sawe HR; Mfinanga JA; Nshom E; Helm E; Moore CG; Runyon MS; Reynolds SL
BMJ Open; 2017 Jul; 7(7):e017190. PubMed ID: 28698351
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
[TBL] [Abstract][Full Text] [Related]
9. Early Initiation of Sub-Anesthetic Ketamine Infusion in Adults with Vaso-Occlusive Crises Is Associated with Greater Reduction in Sickle Cell Pain Intensity: A Single Center's Experience.
Kenney MO; Becerra B; Mallikarjunan A; Shah N; Smith WR
Pain Med; 2022 Dec; 23(12):2042-2049. PubMed ID: 35708641
[TBL] [Abstract][Full Text] [Related]
10. Ketamine for Pain in Sickle Cell Disease Reduces Opioid Usage.
Onyebuchi CO; Chumpitazi CE; Placencia JL; Jackson AN; Jones JL; Torres L; Tubman VN
J Pain Symptom Manage; 2024 Mar; 67(3):e169-e175. PubMed ID: 38000561
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series.
Zempsky WT; Loiselle KA; Corsi JM; Hagstrom JN
Clin J Pain; 2010 Feb; 26(2):163-7. PubMed ID: 20090444
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease.
Puri L; Morgan KJ; Anghelescu DL
Curr Opin Support Palliat Care; 2019 Dec; 13(4):402-407. PubMed ID: 31157658
[TBL] [Abstract][Full Text] [Related]
13. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
Harris EM; Vilk E; Donado C; Williams A; Heeney MM; Solodiuk J; Greco C; Archer NM
Pediatr Blood Cancer; 2023 May; 70(5):e30254. PubMed ID: 36861789
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of ketamine for the management of vaso-occlusive pain in sickle cell disease.
Harris EM; Vilk E; Heeney MM; Solodiuk J; Greco C; Archer NM
Pediatr Blood Cancer; 2021 Jul; 68(7):e28989. PubMed ID: 33788404
[TBL] [Abstract][Full Text] [Related]
15. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM
Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912
[TBL] [Abstract][Full Text] [Related]
16. Low-dose Ketamine Infusion for Pediatric Hematology/Oncology Patients: Case Series and Literature Review.
Yu H; Chen A; Chen E; Long LS; Agrawal AK
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e188-e193. PubMed ID: 34486547
[TBL] [Abstract][Full Text] [Related]
17. Approach to the vaso-occlusive crisis in adults with sickle cell disease.
Yale SH; Nagib N; Guthrie T
Am Fam Physician; 2000 Mar; 61(5):1349-56, 1363-4. PubMed ID: 10735342
[TBL] [Abstract][Full Text] [Related]
18. Comment on: Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
Qureshi AA
Pediatr Blood Cancer; 2023 Nov; 70(11):e30618. PubMed ID: 37558635
[No Abstract] [Full Text] [Related]
19. Reply to: Comment on: Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
Harris EM; Donado C; Archer NM
Pediatr Blood Cancer; 2024 Jan; 71(1):e30740. PubMed ID: 37877853
[No Abstract] [Full Text] [Related]
20. Low dose ketamine use in the emergency department, a new direction in pain management.
Pourmand A; Mazer-Amirshahi M; Royall C; Alhawas R; Shesser R
Am J Emerg Med; 2017 Jun; 35(6):918-921. PubMed ID: 28285863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
